Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Oncology Panel Highlights Trend Toward Being More Selective With Studies

Executive Summary

FDA and the pediatric oncology community are becoming more selective in the cancer drugs they want studied in children.

You may also be interested in...



FDA Pediatric Oncology Advisors Seek Meaningful Trial Plans For Mutually Beneficial Review

As the message that pediatric trials may be necessary or required has apparently gotten across to industry, ODAC’s Pediatric Subcommittee is ready to advise developers on trials that might help improve the way pediatric cancer drugs are developed. Nominations are being accepted for its December meeting.

Pediatric Studies Of Difficult-To-Treat Cancers To Get Advisory Cmte. Review

GlaxoSmithKline's Votrient (pazopanib), Genentech's vismodegib and two investigational drugs will be the subjects for the Pediatric Oncology Subcommittee of FDA's Oncologic Drugs Advisory Committee Nov. 1.

Pediatric Studies Of Difficult-To-Treat Cancers To Get Advisory Cmte. Review

GlaxoSmithKline's Votrient (pazopanib), Genentech's vismodegib and two investigational drugs will be the subjects for the Pediatric Oncology Subcommittee of FDA's Oncologic Drugs Advisory Committee Nov. 1.

Related Content

Topics

UsernamePublicRestriction

Register

PS052913

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel